or Try an Advanced Search...

    Recent News for CYCCP - Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

    Date Title
    Jun 3 Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
    Back to the Main CYCCP Page...